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Abstract
Background: Soil-transmitted helminthiases (STH) are part of the group of neglected tropical diseases traditionally
treated with preventive chemotherapy interventions. In recent years, drug donations have been essential to
expanding preventive chemotherapy and achieving progressive control of morbidity from STH. This study aims to
evaluate the need for anthelminthic medicines during 2020–2030.
Methods: To estimate the need for anthelminthic medicines, we considered three different scenarios: (1) the
control programmes continues to expand coverage and maintains the frequency of drug administration established
at baseline; (2) the programmes continues to expand coverage but adapts the frequency of drug administration
when the STH prevalence is reduced and (3) the STH programme becomes self-sustainable in some endemic
countries.
Results: We estimate that the number of anthelmintic medicines needed to treat school-aged children will increase
by 40% by 2025 and by 52% by 2030 if countries do not change the frequency of preventive chemotherapy
(scenario 1); that the number of tablets needed will reduce by 32.4% by 2025 and by 49.1% in 2030 if endemic
countries reduce the frequency of preventive chemotherapy (scenario 2); and drug donations could be reduced by
54.4% by 2025 and 74.4% by 2030 if some endemic countries could become independent in drug procurement
(scenario 3).
Conclusions: The number of anthelmintic medicines needed to achieve elimination of morbidity due to STH in
school-aged children will decline during 2020–2030. The decline will be substantial if a number of “upper-middle
income” countries in which STH are endemic procure, as expected, anthelminthic medicines independently.
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Background
Soil-transmitted helminthiases (STH) are part of a group
of diseases commonly referred to as neglected tropical
diseases (NTDs) that disproportionately affect
impoverished populations living in areas where financial
resources and access to sanitation are limited [1]. STH
affect approximately one billion people worldwide [2]
and can trigger important health consequences such as
severe anaemia and hamper the cognitive and physical
development of children [1].
Preventive chemotherapy (PC), the large-scale admin-
istration of anthelminthic medicines to populations at
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risk, is the preferred public health intervention for treat-
ment of four NTDs: lymphatic filariasis, schistosomiasis,
onchocerciasis and STH [3]. For STH, the target is, by
2020, to eliminate morbidity by reducing the prevalence
of infections of heavy and moderate intensity to below
2% among school-aged children (SAC) and preschool-
aged children [1]. Because the reservoir of infection in
the environment is perpetuated by inefficient sanitation
[3], the World Health Organization (WHO) recom-
mends that endemic countries maintain PC interven-
tions after morbidity is eliminated, improve coverage of
sanitation to maintain the benefits of PC, evaluate the
epidemiological situation of STH after five consecutive
years of PC and use the decision-tree (Fig. 1) to select
the optimal frequency of PC according to the epidemio-
logical situation resulting from control activities [4].
WHO has promoted the use of PC for treatment of
STH since 2003. Some countries have implemented
several rounds of PC since then and have achieved
high levels of coverage and reduced prevalence and
intensity of STH infection [5], enabling them to re-
duce the need for anthelminthic medicines to main-
tain control of STH [6]. Albendazole and
mebendazole, the medicines required by PC pro-
grammes for treatment of STH, are currently donated
by GlaxoSmithKline and Johnson & Johnson to WHO
for distribution to health ministries in participating
endemic countries.
Scholars have identified the potential negative long-
term impact on public health when donations are dis-
continued as well as the disincentives for generic manu-
facturers to enter the market for anthelminthics [7]. For
this reason, the maintenance of public health interven-
tions after discontinuation of drug donations are a con-
cern. This study addressed two related research
questions:
1) What is the global need for anthelminthic
medicines for PC during 2020–2030? (Given that
many countries in which STH are endemic are
expected to implement progressively five
consecutive years of PC with effective coverage and
to reduce the frequency of the intervention); and.
2) To what extent will the need for drug donations be
reduced? (Given that many countries in which STH
are endemic are expected to reach a level of
development that will facilitate national support of
PC interventions for treatment of STH).
The first part of our hypothesis is that by 2030, the
quantities of anthelminthics needed globally will re-
duce because of the impact of PC programmes on the
prevalence of STH infection. The second part of our
hypothesis is that some endemic country will progres-
sively assume financial responsibility for deworming
programmes.
Fig. 1 World Health Organization decision-tree (from WHO 2011). STH: Soil-transmitted helminthiases
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Methods
We conducted our study in several phases. First, we
estimated for all countries in which STH are endemic
the expected dates for achieving the 75% coverage
target and the year in which all countries would
complete five consecutive years of PC with effective
coverage. Secondly, we estimated the number of chil-
dren expected to be treated annually in each endemic
country and the number of tablets needed annually
until completion of five rounds of PC. Finally, we es-
timated which countries would be able to conduct PC
independently. The software for statistical analysis R
(https://www.r-project.org/) was used to analyse the
data.
Estimated year in which each endemic country will reach
the coverage target
The WHO PCT databank [8], an online WHO dataset,
contains information for all countries in which STH are
endemic on the number of children needing PC and
the annual rate of coverage since 2006. Each endemic
country has followed a unique path for implementing
STH control programmes, and PC has started at differ-
ent times and achieved different levels of coverage.
First, we extracted from the PCT databank the coun-
tries that had already reached effective coverage (i.e.
75% national coverage). Countries that had imple-
mented three or more years of PC with effective cover-
age from 2011 to 2017 belonged to category A. The
remaining endemic countries were divided into three
subgroups, according to their mean levels of coverage
during the seven years 2011–2017, in order to capture
the level of effective coverage in each country in 2017.
Countries with a mean coverage level of 50–75% were
classified as category B (effective coverage not reached
and high coverage level). Countries with a mean cover-
age level of 20–50% were classified as category C (ef-
fective coverage not reached and average coverage
level). Countries with a mean coverage level of 0–20%
were placed in category D (effective coverage not
reached and low coverage).
The three categories were then attributed different
expectations on how long it would take each to reach
the 75% coverage target: for each endemic country in
category B, we assigned the regional average time
minus the standard deviation (SD), for each endemic
country in category C, we assigned the regional average
time and for each endemic country in category D we
assigned the regional average plus the SD. The SD was
added or subtracted to the projected number of years
as a proxy for the progress countries had made until
2017 in increasing their coverage rates. Table 1 summa-
rizes this model.
Estimated year for achieving five years of effective
coverage
To estimate the data in which each endemic country
completed five years of effective coverage, we added five
years to the year in which the country was estimated to
reach effective coverage for the first time. For some en-
demic countries this date was in the past. For countries
in category A, if PC with effective coverage was imple-
mented for more than three years between 2010 and
2017, we subtracted the years they implemented PC with
at least 75% coverage from the five total years required
by WHO. This took into account deworming efforts
made until now. For all countries, the required five years
of PC with at least 75% coverage were assumed to have
achieved a stable coverage level of 75%.
Estimated number of children needing annual PC for
treatment of STH
To estimate the number of tablets needed, we first cal-
culated the number of children that needed to be cov-
ered each year.
To obtain the number of children to be treated annu-
ally, we multiplied the number of children requiring
treatment in each country by the coverage rate that we
expected for each year. The number of children requir-
ing treatment was adjusted according to the rates (%) of
national population growth for 2017 from the World
Bank. For countries that had not reached effective cover-
age in 2017, the annual increase in coverage rates was
calculated by dividing the coverage gap by the number
of years we expected it would take them to reach the
target.
Estimated total number of tablets needed globally
In many STH-endemic countries some areas require two
rounds of PC a year and other areas require one. Mupfa-
soni et al. [6] calculated that, given the differing fre-
quency of PC, the average mean number of tablets
needed for each child is 1.6. For this reason, we pro-
jected the total number of children to be treated each
year and multiplied it by 1.6 to obtain the number of
tablets to be distributed every year.
We considered two scenarios:
Scenario 1: Endemic countries, after five years of
implementing PC, maintain the frequency of the inter-
vention according to the prevalence at baseline. The
number of tablets needed globally increases progressively
with the increase in the number of endemic countries
achieving effective coverage and the rate of expected
population growth in each country.
Scenario 2: Endemic countries, consequent to the re-
duction in prevalence obtained after five years of PC, re-
duce the frequency of the intervention as indicated in
the WHO decision-tree (Fig. 1).
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To calculate the extent of the reduction in the
number of tablets needed, we used the study by Mup-
fasoni et al. [6] that in 2018 examined the 15 coun-
tries in all WHO regions to measure changes in STH
prevalence after five years of PC and the consequent
reduction in need for anthelminthics. The average re-
duction in STH prevalence was estimated at 70% and
the need for anthelminthics was 36%. The reduction
of 36% was applied to the number of tablets needed
after five years of effective coverage, resulting in a
second scenario of future drug needs.
Independence from drug donations
Scenario 3: We defined a third scenario considering
the possibility that countries could support school-
based deworming programmes through domestic re-
sources. To do so we divided all STH endemic coun-
tries according to the World Bank income groups
based on gross national income (GNI) per capita
(Table 2).
We chose this method because it models the strategy
used by multilateral donors to elaborate the eligibility
criteria for donations. Moreover, GNI per capita is a
reliable indicator of economic growth, which itself is a
known driver of expansion of fiscal space.
We considered that countries in the high-income and
upper-middle income groups could become independent
from 2022. We considered the cost per school child
dewormed (USD 0.10–0.20) [4] to be marginal for those
high-income and upper-middle income countries whose
total health expenditures amount to at least USD 461
per capita.
On the opposite side, countries in the low-income
group were attributed full continuation of drug dona-
tions because they are the group with the smallest fiscal
space and therefore with the most reduced ability to take
responsibility for drug procurement.
The lower-middle income group was subjected to a
different analysis based on the projections of three
health financing indicators: (i) projections for total
health spending per capita (2016 US dollars); (ii) projec-
tions for government spending as a percentage of total
health spending; (iii) projections for total health spend-
ing as a percentage of gross domestic product (GDP).
The projected levels of health expenditure were
compared with cut-offs derived from the results of a
recent (2019) study that summarized the average
Table 1 Country categorization and relevant weight given to deworming efforts already accomplished
Country category Country code Criteria Effect on estimated years left to reach
effective coverage
Effective coverage reached A Since 2010 more than 3 years
coverage ≥ 75%
Already achieved
Not reached and high coverage B Since 2010 less than 3 years
coverage ≥ 75% +mean
coverage 50% < x < 75%
Regional average duration taken to reach
target - SD
Not reached and average coverage C Since 2010 less than 3 years
coverage ≥ 75%, + mean
coverage 20% < x < 50%
Regional average duration taken to reach
target
Not reached and low coverage D Since 2010 less than 3 years
coverage ≥ 75%, + mean
coverage < 20%
Regional average duration taken to reach
target + SD
SD standard deviation
Table 2 World Bank income group (2016) and minimum levels of health financing [9] and expected national self-financing of school
deworming












Expected independency form drug
donations
High income 12 056 4 5184 0.782 Independent from 2022 onwards
Upper middle income 3896/12 055 28 461 0.499 Independent from 2022 onwards
Lower middle income 996/3895 35 74 0.284 Progressively independent procurement
from 2022 onwards based of comparison
of projected health financing levels to
minimum levels of 2016
Low income 995 32 38 0.233 Non-independent before 2030
GNI gross national income, STH soiltransmitted helminthiases, USD United States dollar
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levels of health financing in 2016 for each World
Bank income group [9]. For each indicator, countries
with projected levels equal to or greater than the
minimum of their income group for 2016 had their
drug donations progressively reduced until 2030 ac-
cording to the matrix indicated in Table 3. The re-
duction was applied from 2022 based on the
reference number of tablets found under scenario 2.
We chose to attribute more weight to the variable of
government health expenditures per total health ex-
penditures than the other variables in order to dem-
onstrate the importance of public engagement against
NTDs. The rationale is that national projected levels
of health financing, assumed to be higher than the
levels in 2016, can be used as a proxy to model the
increased ability of governments to assume responsi-
bility for deworming programmes and therefore to de-
crease the quantities of drug donations received.
Results
Estimated year in which endemic countries reach the
coverage target and estimated year for completion of five
years of PC for treatment of STH
The average time to reach effective coverage in each
WHO region was: 5.1 ± 2.5 years in the African Region
(AFR); 5.2 ± 3 years in the Region of the Americas
(AMR); 7 ± 1 years in the Eastern Mediterranean Region
(EMR); 5.2 ± 2.6 years in the European Region (EUR);
4 ± 3 years in the South-East Asia Region (SEAR); and
5.1 ± 2.4 years in the Western Pacific Region (WPR).
Table 4 shows the number of countries in each WHO
region for the different categories, the number of years
to reach effective coverage and the number of years to
reach five years of effective coverage. Globally, 38 en-
demic countries have reached effective coverage (cat-
egory A), five countries have not reached effective
coverage but have high coverage (category B), 18 coun-
tries have not reached effective coverage and are in the
average group (category C) and 41 countries fall into the
category of countries that have implemented PC with
low coverage (category D).
Figure 2a–f shows the years in which countries will
reach effective coverage in the different regions. All
countries in AFR, AMR and EMR are expected to reach
75% coverage by 2026; this target is expected to be
reached in 2025 by WPR and EUR countries and in
2019 in SEAR countries.
While estimating the year in which each endemic
country is expected to reach effective coverage we also
estimated annual coverage for each endemic country.
Estimated number of children needing annual PC for
treatment of STH
Table 5 presents the global number of children need-
ing PC for treatment of STH, the total number of
children expected to be treated and the global cover-
age of PC. The total number of SAC in need of
deworming is expected to increase from 604 million
in 2017 to 754 million in 2030, because of the demo-
graphic increase in the population in endemic coun-
tries, and the coverage is expected to increase from
61% in 2017 to 75% in 2026.
Estimated total number of tablets needed globally
Table 6 presents the number of tablets needed globally
according to scenarios 1 and 2; data for each endemic
country are included in the supplementary dataset. In
the absence of reduced PC frequency (scenario 1), the
need for anthelminthics is expected to reach approxi-
mately 900 million tablets in 2030. However, should
countries reduce the frequency of the intervention ac-
cording to the WHO decision-tree (Fig. 1, scenario 2),
the need for anthelminthics will be reduced to 460 mil-
lion in 2030.
Independence from drug donations
In scenario 3, we assumed that countries in the high-income
and upper-middle income groups of the World Bank could
become progressively independent from drug donations by
Table 3 Criteria for determining the reduction in the number of tablets for lower middleincome countries
National projection equal to or greater
than health spending per capita
(US$ 2016)
National projection equal to or
greater than health spending per
GDP (2016)
National projection equal to or greater than











YES YES YES -80%
GDP gross domestic product
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using domestic resources to procure the anthelminthics
needed in school-based deworming programmes.
Table 2 shows the number of endemic countries clas-
sified by World Bank income group.
In total:
 4 endemic countries were classified as high-income
and 28 as upper-midle income and are therefore ex-
pected to become independent in supporting PC for
treatment of STH from 2022;
 35 endemic countries were classified as lower-middle
income and are therefore expected to become pro-
gressively independent between 2022 and 2030; and
 32 endemic countries were classified as low-income
and are therefore expected to continue to receive
full external support until 2030.
Under scenario 3 we observed that the number of “do-
nated” tablets needed globally decreases by 39.9% by
2025 and by 49.7% by 2030 compared with the number
of tablets estimated under scenario 2. Compared with
the forecast obtained under scenario 1, this change rep-
resents a 59.4% reduction by 2025 and a 74.4% reduction
by 2030. The WHO African and South-East Asia regions
are the main regions that will continue to need drug do-
nations until at least 2030. This can be explained by the
predominance of low-income and lower-middle income
countries in these regions. Figure 3 compares the esti-
mated number of tablets needed according to the three
scenarios.
Sensitivity analysis
As reported in Table 6, a 20% univariate sensitivity ana-
lysis was conducted to evaluate the variability of the re-
sults when national projections for the three health
financing indicators are varied by 20%. We created an
interval within which we believe the numbers found
under scenario 3 are likely to vary.
The numbers of tablets needed in scenarios 2 and 3
reduce to 50.6% by 2025 and to 53.1% by 2030 if we as-
sume that national projections on health spending are
20% higher than those reported by the Institute for
Health Metrics and Evaluation. These numbers reduce
further to 25.6% by 2025 and to 27.9% by 2030 in a sce-
nario in which national health financing projections are
20% less than the findings of the Institute for Health
Metrics and Evaluation.
Table 4 Number of countries in the four categories (A, effective coverage target reached; B, target not reached yet with high level
of coverage during the past seven years; C, target not reached yet with average coverage during the past 7 years; D, target not





Mean years left to
effective coverage
Mean annual increase in
coverage until effective coverage
Years left to the end of
5 years with effective coverage
African A 17 0 NA 0.9
B 3 2.5 6.8 7.5
C 6 5.1 8.3 10.1
D 15 7.6 8.6 12.6
Americas A 7 0 NA 0.7
B 1 2.2 9.5 7.2
C 4 5.2 7.3 10.2
D 13 8.2 8.8 13.2
Eastern
Mediterranean
A 1 0 NA 2
C 1 7 6 12
D 5 8 8.6 13
European A 2 0 NA 0.5
C 2 5.2 7 10.2
D 2 7.8 8.9 12.8
South-East Asia A 6 0 NA 1
B 1 1 10.3 6
C 1 4 12.8 9
Western Pacific A 5 0 NA 0.8
C 4 5.1 7.3 10.1
D 6 7.6 9.5 12.6
NA not applicable
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In scenarios 1 and 3, the numbers of tablets needed
are reduced to 66.6% by 2025 and to 76.1% by 2030 if
we assume national health spending will be 20% higher
than those projected by the Institute for Health Metrics
and Evaluation. They reduce to 49.7% by 2025 and to
63.3% by 2030 should the national health financing be
20% less than the projections of the Institute for Health
Metrics and Evaluation.
Discussion
Our findings on the effective coverage target are
promising: by 2030 all endemic countries will have
Fig. 2 Expected year of achievement of coverage target for STH-endemic countries by WHO region: a African Region; b Region of the Americas;
c South-East Asia Region; d European Region; e; Eastern Mediterranean Region; f Western Pacific Region. STH: Soil-transmitted helminthiases;
WHO World Health Organization
Table 5 Global annual projections of the total number of school-aged children (SAC) requiring preventive chemotherapy (PC) and
the total number of children effectively treated
Year Number of SAC requiring PC (in thousands) Number of SAC effectively treated (in thousands) Global coverage (%)
2017 604 085 369 846 61.2
2018 614 252 397 476 64.7
2019 624 630 421 776 67.5
2020 635 224 439 394 69.2
2021 646 039 455 471 70.5
2022 657 082 471 535 71.8
2023 668 357 487 638 73.0
2024 679 870 503 250 74.0
2025 691 627 517 821 74.9
2026 703 635 527 564 75.0
2027 715 899 536 924 75.0
2028 728 426 546 319 75.0
2029 741 222 555 916 75.0
2030 754 294 565 721 75.0
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Table 6 Global annual projections of numbers of tablets needed under scenarios 1, 2 and 3
Year Scenario 1
Total no. of tablets (in thousands) with
no consideration of impact of
deworming programmes on prevalence
reduction
Scenario 2
Total no. of tablets (in thousands) with 36%
reduction in no. of tablets needed following
prevalence reduction every five years of PC
implementation with effective coverage
Scenario 3
Total no. of tablets (in thousands) with
progressive phasing out of drug donations.
Results of univariate sensitivity analysis in
parenthesis.
2017 591 751 546 603 546 603
2018 635 958 585 432 585 432
2019 674 838 534 948 534 948
2020 703 027 561 139 561 139
2021 728 749 584 828 584 828
2022 754 452 577 459 370 224 (284 943–450 908)
2023 780 215 594 601 377 245 (290 609–461 146)
2024 805 194 540 395 325 958 (267 142–402 721)
2025 828 508 559 632 335 943 (276 153–415 993)
2026 844 095 551 456 333 383 (272 740–393 256)
2027 859 071 489 806 300 247 (240 639–348 937)
2028 874 104 496 910 304 582 (244 205–354 161)
2029 889 459 470 456 288 683 (228 751–338 970)
2030 905 146 460 526 231 507 (215 746–331 983)
PC preventive chemotherapy
Fig. 3 Summary graph of the three scenarios of projections for total number of tablets donated annually until 2030.
Three scenarios are presented:
Scenario 1: Endemic countries would continue to increase coverage and maintain the same frequency of intervention.
Scenario 2: Endemic countries would reduce the frequency of intervention when the STH prevalence is reduced, according to the WHO decision-tree.
Scenario 3: Some endemic countries would sustain the cost of the deworming programme, depending on the levels of development
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reached the target of implementing five consecutive
years of PC with effective coverage. We have demon-
strated that STH morbidity reduces significantly after
5 years of PC [10]. We therefore believe that
achievement of target 3.3 of Sustainable Development
Goal 3 (“Ensure healthy lives and promote well-being
for all at all ages”), which extends Millennium Devel-
opment Goal 3 beyond HIV, TB and malaria to “end
the epidemics” of NTDs by 2030 [11] is feasible for
STH.
The reduction in the total number of tablets donated
by pharmaceutical companies as estimated in this study
is relevant, but our estimates are conservative for the fol-
lowing reasons:
 Our method for defining when a country reached
effective coverage (based on average levels over 7
years) is stricter than that normally used by WHO,
which considers that the effective coverage is
reached when a country reaches this level for the
first time; and
 Rapid economic development may result in
countries shifting from the low-income group to the
lower-middle income group or from lower-middle
income to upper-middle income countries.
We therefore consider that the number of donated
tablets needed may reduce more rapidly than estimated.
To measure countries’ ability to implement deworm-
ing programmes independently, we took into account
variables related to their level of development and meas-
ure of welfare (World Bank income groups) and to
health financing. GNI per capita, based on a determin-
ation of income group thresholds, has limitations as an
indicator of wealth and development. GNI, calculated as
GDP plus net receipts from abroad of wages and salaries
and of property income plus net taxes and subsidies re-
ceivable from abroad [12], does not capture inequalities
and income distribution (OECD, 2012). This idea was
first explored by the economist Amartya Sen who
showed that societies’ level of well-being is determined
not only by its level of net income per capita but also by
how that income is used and distributed [13]. Moreover,
the concept of economic development as measured by
traditional instruments (GDP, GNI) fails to acknowledge
the choices of how income is used and can therefore bias
estimates of the magnitude of efforts by countries to in-
crease the well-being of their populations. GNI per
capita may be a good theoretical tool for measuring
countries’ ability to finance deworming programmes in-
dependently, but it is insufficient on its own. Other in-
struments such as the human development index (HDI)
might also be a good indicator of exogenous elements,
such as political will, which are likely to influence how
priorities are identified when States elaborate annual
budgets and plan national public health programmes
[14]. The division of countries into no reduction, pro-
gressive reduction and total discontinuation groups for
drug donations according to the World Bank income
groups is thus driven only by the necessity to rely on
available estimates of internationally comparable num-
bers. The additional consideration of health financing in-
dicators, at least for the group of low-middle income
countries, is also an attempt to include and “control” for
other factors that have an impact on NTDs, in addition
to GNI per capita.
A strategy to progress phasing out of drug donations
should nevertheless be carefully organized to ensure that
programmes are not interrupted. Additional elements
that influence a country’s ability to become independent
in the fight against NTDs should be taken into
consideration.
We were unable to include the following elements in
our analysis:
 The possible contribution of improvements in water
management and sanitation systems because of the
difficulty in predicting investments in this sector;
however, substantial global improvement in access
to water and sanitation is expected to result from
efforts to reach Sustainable Development Goal (Goal
6: Clean water and sanitation) [15];
 The expected improvement in the quality of
education (Goal 4: Quality education), especially if
targeted towards maternal education, which is
known to accelerate elimination of NTDs [16];
however, it is very difficult to quantify the impact of
girls’ education today in reducing the risky
behaviours among and reinfection of children
tomorrow; and
 the expected progress in elimination of poverty
(Goal 1: No poverty) that will entail substantial
reduction in STH endemicity [17].
Again, if all these goals are reached the reduction in
the need for donated drugs to control STH could be
greater than estimated.
Conclusions
Coverage of PC for treatment of STH has increased in
recent years, yielding benefits for control of morbidity
tomorrow, important increases in adults’ productivity
and high returns on public investment. The prospect of
progressively reducing drug donations for PC creates a
case for countries to prioritize the fight against NTDs.
Our study found that during 2020–2030, all countries in
which STH are endemic are expected to reach the effect-
ive coverage target and that improved STH
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epidemiology will reduce the number of tablets needed
to implement PC globally. Moreover, thanks to the re-
duction of the total cost of PC associated with these epi-
demiological improvements, the magnitude of required
deworming programmes will also shrink considerably,
making it more affordable for endemic countries to as-
sume implementation of PC. Low-income countries will
likely not become independent in implementing PC be-
cause of the current low level of development and the
limited improvements expected in the next 10 years.
Therefore, while donations of anthelminthic medicines
will continue to be necessary, the number of donated an-
thelmintic tablets needed will reduce by 74.4%.
We should not forget that the permanent elimination
of STH is feasible only with the elimination of environ-
mental contamination, which can be achieved by drastic-
ally improving the coverage of sanitation and promoting
behavioural change.
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